How the GLP-1 Drug Exendin-4 Changes Brain Chemistry in the Reward Center of Rats | Research

The takeaway

Exendin-4 reduced taurine and glycine levels in the brain's reward center of rats, partly through a brainstem relay — offering clues to how GLP-1 drugs may dampen reward-seeking behavior.

Reward center chemistry altered
Exendin-4 reduced taurine and glycine in the nucleus accumbens via a brainstem pathway, potentially explaining why GLP-1 drugs decrease reward-seeking behavior

What the researchers found

The GLP-1 receptor agonist exendin-4 (Ex4) reduced levels of taurine, glycine, and serine in the nucleus accumbens — the brain's reward center — of male rats. The decreases in taurine and glycine appeared to involve GLP-1 receptor activation in the nucleus tractus solitarius (NTS), a brainstem region that relays gut signals to the brain.

Systemic Ex4 injection also elevated metabolites of dopamine (DOPAC and HVA) and serotonin (5HIAA) in the nucleus accumbens. The dopamine-related metabolite increases involved GLP-1 receptors outside the NTS, suggesting multiple brain pathways are involved in how GLP-1 drugs modulate reward-related behavior.

Why it matters

GLP-1 drugs like semaglutide and exenatide are increasingly observed to reduce not just appetite but also interest in alcohol, gambling, and other addictive behaviors. This study helps explain the brain chemistry behind these effects by showing that a GLP-1 agonist changes neurotransmitter levels in the reward center. Understanding these mechanisms could open the door to using GLP-1 drugs for addiction treatment.

The numbers in context

Ex4 reduced taurine, glycine, and serine in nucleus accumbens · elevated DOPAC, HVA, and 5HIAA · NTS involvement confirmed for taurine and glycine effects · systemic and local NTS administration compared

How the study worked

This exploratory study used in vivo microdialysis in male rats — a technique that samples brain chemicals in real time through a tiny probe. Exendin-4 was administered either systemically (whole-body injection) or locally into the NTS. Researchers then measured changes in multiple neurotransmitters and their metabolites in the nucleus accumbens, including dopamine, serotonin, noradrenaline, glutamate, GABA, glycine, taurine, and serine.

Who was studied

Male rats studied via in vivo microdialysis

What this study cannot tell us

This is a descriptive animal study that shows correlations but cannot prove causality. Only male rats were studied, so sex differences are unknown. The study used exendin-4, which may not perfectly replicate the effects of longer-acting GLP-1 drugs like semaglutide used clinically. The authors explicitly note the descriptive nature of the findings.

How to read the evidence

This is a preliminary exploratory animal study using in vivo microdialysis. While the technique provides direct measurement of brain chemistry, the study is descriptive and cannot establish causality.

When this study was published

Published in 2024, this is very recent research addressing one of the hottest questions in GLP-1 pharmacology — how these drugs affect the brain's reward system.

The bigger picture

The observation that GLP-1 drugs reduce addictive behaviors has generated enormous interest. This study adds neurochemical detail to that picture by identifying specific neurotransmitter changes in the reward center. If confirmed, this could support repurposing GLP-1 agonists for alcohol use disorder, gambling addiction, and other compulsive behaviors — extending their impact far beyond metabolic disease.

Questions still open

Would longer-acting GLP-1 agonists like semaglutide produce the same neurochemical changes in the nucleus accumbens?
Do these neurochemical changes in the reward center directly cause reduced interest in alcohol and other rewards?
Are there sex differences in how GLP-1 agonists affect brain reward chemistry?

Common questions

Why would a diabetes drug change brain chemistry in the reward center?

GLP-1 receptors aren't just in the gut and pancreas — they're also found throughout the brain, including in areas that process reward and motivation. When GLP-1 drugs activate these brain receptors, they can change the levels of neurotransmitters involved in how we experience pleasure and motivation, which may explain why some people on these drugs report less interest in alcohol and other rewards.

What are taurine and glycine doing in the brain's reward center?

Taurine and glycine are amino acids that also act as neurotransmitters in the brain. In the nucleus accumbens (reward center), they help modulate how neurons communicate about pleasure and motivation. When exendin-4 reduced their levels, it likely changed how the reward circuit processes information, potentially making rewarding stimuli feel less compelling.

Read the original research

The GLP-1 receptor agonist exendin-4 reduces taurine and glycine in nucleus accumbens of male rats, an effect tentatively involving the nucleus tractus solitarius.

Frontiers in pharmacology, 15, 1439203

View on PubMed ↗Publisher’s paper ↗

Citation

Edvardsson, Christian E; Vestlund, Jesper; Ericson, Mia; Jerlhag, Elisabet. (2024). The GLP-1 receptor agonist exendin-4 reduces taurine and glycine in nucleus accumbens of male rats, an effect tentatively involving the nucleus tractus solitarius.. Frontiers in pharmacology, 15, 1439203. https://doi.org/10.3389/fphar.2024.1439203